S-1: Phio Pharmaceuticals Files for Resale of Up to 1,131,468 Common Shares

Phio Pharmaceuticals has filed a registration statement for the resale of up to 1,131,468 shares of common stock by selling stockholders, primarily related to warrant exercises.

Summary

• Phio Pharmaceuticals has filed a Form S-1 registration statement with the SEC regarding the resale of up to 1,131,468 shares of its common stock.
• These shares are issuable upon the exercise of warrants held by selling stockholders.
• The warrants include Series C Warrants (up to 583,098 shares), Series D Warrants (up to 507,474 shares), and warrants issued to the placement agent (up to 40,896 shares).
• Phio Pharmaceuticals will not receive any proceeds from the sale of these shares by the selling stockholders, except when the warrants are exercised for cash.
• If all warrants are exercised for cash, Phio Pharmaceuticals estimates it would receive gross proceeds of approximately $6.2 million.
• The company intends to use any proceeds received from the cash exercise of the warrants to fund the development of its product candidates, other research and development activities and for general working capital needs.
• The company's common stock is listed on The Nasdaq Capital Market under the symbol PHIO.
• On July 25, 2024, the last reported sale price of Phio's common stock on The Nasdaq Capital Market was $3.8467 per share.
• The company completed a 1-for-9 reverse stock split of its outstanding Common Stock on July 5, 2024.
• As of March 31, 2024, the company had 510,188 shares of Common Stock outstanding.

Sentiment

Score: 6

Explanation: The document is primarily a registration statement, which is neutral in tone. The potential for a $6.2 million capital raise is a positive, but the risks associated with the company's early-stage development and dependence on its INTASYL platform temper the overall sentiment.

Positives

• Potential for Phio Pharmaceuticals to receive approximately $6.2 million in gross proceeds if all warrants are exercised for cash.
• The company has the flexibility to use the proceeds for research and development, and general working capital.
• The company's INTASYL platform has potential benefits including the ability to target a broad range of cell types and tissues, target both intracellular and extracellular protein targets, efficient uptake by target cells, avoiding the need for assisted delivery, sustained, or long-term, effect in vivo, ability to target multiple genes in one drug product, favorable clinical safety profile with local administration, and readily manufactured under current good manufacturing practices.

Negatives

• Phio Pharmaceuticals will not receive any proceeds from the sale of common stock by the selling stockholders unless the warrants are exercised for cash.
• There is no guarantee that the warrants will be exercised, and the company may not receive any cash proceeds.
• The company is dependent on the success of its INTASYL technology platform, and its product candidates based on this platform, which is unproven and may never lead to approved and marketable products.
• The company's product candidates are in an early stage of development and the company may fail, experience significant delays, never advance in clinical development or not be successful in its efforts to identify or discover additional product candidates, which may materially and adversely impact the company's business.
• The company may not be able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market.
• The price of the company's common stock has been and may continue to be volatile.

Risks

• The company's dependence on the success of its INTASYL technology platform.
• The early stage of development of the company's product candidates.
• Potential delays or difficulties in identifying and enrolling subjects in clinical trials.
• Reliance on third parties for the manufacture of clinical supply for product candidates.
• Potential computer system failures, cyberattacks, or deficiencies in cybersecurity.
• Dependence on patents and licensed technologies.
• The need for substantial additional funds to complete research and development activities.
• Potential volatility in the price of the company's common stock.
• The company may not be able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market.

Future Outlook

Phio Pharmaceuticals intends to use any proceeds received from the cash exercise of the Warrants to fund the development of its product candidates, other research and development activities and for general working capital needs. The company may also use a portion of any proceeds received by us from the cash exercise of the Warrants to acquire or invest in complementary businesses, products and technologies or to fund the development of any such complementary businesses, products or technologies.

Industry Context

Phio Pharmaceuticals is operating in the immuno-oncology therapeutics space, focusing on RNAi technology. This area has seen significant investment and competition, with companies like Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals leading the way in RNAi-based therapeutics. Phio's INTASYL platform aims to differentiate itself through its self-delivery mechanism, potentially offering advantages over other siRNA technologies that require specialized delivery systems.

Comparison to Industry Standards

• Phio's approach to immuno-oncology using RNAi technology can be compared to companies like Alnylam Pharmaceuticals, which has successfully developed and commercialized RNAi-based therapeutics.
• However, Alnylam's focus is primarily on rare genetic diseases, while Phio is targeting cancer.
• Arrowhead Pharmaceuticals is another competitor in the RNAi space, with a focus on liver-targeted therapies.
• Phio's self-delivery INTASYL platform differentiates it from these companies, as it aims to eliminate the need for specialized delivery systems.
• The Phase 1b clinical trial for PH-762 is similar to early-stage trials conducted by other biotech companies developing novel cancer therapies.
• Success in this trial would be a significant milestone for Phio and would position it more competitively in the immuno-oncology market.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised and new shares are issued.
• Employees may benefit from the company's continued research and development efforts.
• Customers (potential patients) may benefit from the development of new cancer therapies.
• Suppliers and creditors may benefit from the company's increased financial stability if the warrants are exercised.

Next Steps

• The selling stockholders may offer the shares for resale from time to time.
• Phio Pharmaceuticals will continue to develop its product candidates and conduct its Phase 1b clinical trial with PH-762.
• The company expects to complete enrollment of patients in the second quarter of 2025.

Key Dates

Keywords

Phio Pharmaceuticals, common stock, warrants, resale, registration statement, INTASYL, PH-762, selling stockholders, clinical trial, financing